Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

Arthritis Research and Therapy

Volumn 8, Issue 4, 2006, Pages

  Hamdi, Haïfa ^a   Mariette, Xavier ^b   Godot, Véronique ^a   Weldingh, Karin ^c   Hamid, Abdul Monem ^d   Prejean, Maria Victoria ^a   Baron, Gabriel ^e   Lemann, Marc ^f   Puechal, Xavier ^g   Breban, Maxime ^h   Berenbaum, Francis ⁱ   Delchier, Jean Charles ^j   Flipo, René Marc ^k   Dautzenberg, Bertrand ^l   Salmon, Dominique ^m   Humbert, Marc ^d   Emilie, Dominique ^a,d   Meyer, Olivier ^e   Falgarone, Géraldine ⁿ   Chaussade, Pierre ^m   Desreumaux, Xavier ^k   Liote, Frédéric ^o   Claudepierre, Pascal ^j   Portier, Alain ^p   Bacchi, Véronique Fremeaux ^p   more..

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c STATENS SERUM INSTITUT   (Denmark)

^d HÔPITAL ANTOINE BÉCLÈRE   (France)

^e BICHAT HOSPITAL   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g CENTRE HOSPITALIER DU MANS   (France)

^h HÔPITAL AMBROISE PARÉ   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

^j HENRI MONDOR HOSPITAL   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m NONE   (France)

ⁿ AVICENNE HOSPITAL   (France)

^o HÔPITAL LARIBOISIÈRE   (France)

^p HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CFP-10 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUBERCULIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CELL CULTURE; COMPLICATION; CROHN DISEASE; DRUG ADMINISTRATION; DRUG EFFECTS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; T LYMPHOCYTE; TUBERCULOSIS;

ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, BACTERIAL; ARTHRITIS, RHEUMATOID; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHROPATHIES; T-LYMPHOCYTES; TUBERCULIN; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS;

EID: 70350607858     PISSN: 14786354     EISSN: 14786362     Source Type: None    
DOI: 10.1186/ar1994     Document Type: Article

References (48)

1. Olsen NJ, Stein CM: New drugs for rheumatoid arthritis. N Engl J Med 2004, 350:2167-2179.
2. Bang LM, Aeating GM: Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs 2004, 18:121-139.
3. Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. Arthritis Rheum 2003, 48:3230-3236.
4. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, et al.: Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
5. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ, Crohn's Disease cA2 Study Group: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997, 337:1029-1035.
6. Mease P: TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004, 63:755-758.
7. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study Group: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003, 349:2014-2022.
8. Lahdenne P, Vahasalo P, Honkanen V: Infliximab in the treatment of children with refractory juvenile idiopathic arthritis: An open label study. Ann Rheum Dis 2003, 62:245-247.
9. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
10. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127.
11. Ellerin T, Rubin RH, Weinblatt ME: Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003, 48:3013-3022.
12. Wallis RS, Broder M, Wong J, Beenhouwer D: Granulomatous infections due to tumor necrosis factor blockade: Correction. Clin Infect Dis 2004, 39:1254-1255.
13. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, et al.: Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005, 52:1986-1992.
14. +T cell clones provides a costimulatory signal for human B cell activation. J Exp Med 1993, 177:1575-1585.
15. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
16. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase- dependent pathway. Gastroenterology 2001, 121:1145-1157.
17. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989, 56:731-740.
18. Kaneko H, Yamada H, Mizuno S, Udagawa T, Kazumi Y, Sekikawa K, Sugawara I: Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factoralpha-deficient mice. Lab Invest 1999, 79:379-386.
19. Olleros ML, Guler R, Corazza N, Vesin D, Eugster HP, Marchal G, Chavarot P, Mueller C, Garcia I: Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 2002, 168:3394-3401.
20. Botha T, Ryffel B: Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 2003, 171:3110-3118.
21. Saunders BM, Briscoe H, Britton W: T cell-derived tumor necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection. Clin Exp Immunolu 2004, 137:279-287.
22. Saunders BM, Tran S, Ruuls S, Sedgwick JD, Briscoe H, Britton WJ: Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not longterm, control of Mycobacterium tuberculosis infection. J Immunol 2005, 174:4852-4859.
23. Mariette X, Salmon D, RATIO Group: French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated With TNF blockers. Ann Rheum Dis 2003, 62:791-792.
24. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF: Tuberculosis Associated With Therapy Against Tumor Necrosis Factor. Arthritis Rheum 2005, 52:2968-2974.
25. British Thoracic Society Standards of Care Committee: BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF treatment. Thorax 2005, 60:800-805.
26. Andersen P, Munk ME, Pollock JM, Doherty TM: Specific immune-based diagnosis of tuberculosis. Lancet 2000, 356:1099-1104.
27. Arend SM, Andersen P, van Meijgaarden KE, Skjot RL, Subronto YW, van Dissel JT, Ottenhoff TH: Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. J Infect Dis 2000, 181 1850-1854.
28. Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, Reece WH, Latif M, Pasvol G, Hill AV: Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001, 357:2017-2021.
29. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM: A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002, 57 804-809.
30. Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, Monk P, Lalvani A: Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003, 361:1168-1173.
31. Brock I, Weldingh K, Leyten EM, Arend SM, Ravn P, Andersen P: Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol 2004, 42:2379-2387.
32. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P: Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004, 170:65-69.
33. Harboe M, Malin AS, Dockrell HS, Wiker HG, Ulvund G, Holm A, Jorgensen MC, Andersen P: B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis. Infect Immun 1998, 66 717-723.
34. Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P, Gicquel B: A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP- 10). Microbiology 1998, 144:3195-3203.
35. Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, Michon C, Oksenhendler E, Weiss L, Gastaut JA, et al.: Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: A randomised controlled trial AIDS 2003, 17:343-351.
36. +T cells proliferating to grass pollen in seasonal allergic subjects by flow cytometry. Clin Exp Immunol 2003, 132:76-80.
37. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ: Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 50:353-363.
38. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC: The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:1451-1459.
39. Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L: Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors Ann Rheum Dis 2001, 60:133-139.
40. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, Pastor C, Harrison J, Sanchez-Schwartz C: Attenuated response to purified protein derivative in rheumatoid arthritis patients. Study in a population with high prevalence of tuberculosis. Ann Rheum Dis 2005, 64:1360-1361.
41. Greenberg J, Schloss S, Kurucz O, Reddy S, Abellana V, McCullagh E, Abramson S, Bingham C: Pilot Study of Tuberculosis Screening Strategies for Rheumatoid Arthritis Patients [abstract]. Arthritis Rheum 2005, 52:s545.
42. O'Shea FD, Kavanagh PJ, Cassidy A, Anwar A, McCarthy GM, McCarthy CJ: The impact of steroid use on mantoux testing in patients undergoing screening for anti-TNF medication [abstract]. Arthritis Rheum 2005, 52:s569.
43. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J: Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003, 48:780-790.
44. Vigna-Pérez M, Abud-Mendoza C, Portillo-Salazar H, Alvarado- Sánchez B, Cuevas-Orta E, Moreno-Valdés R, Baranda L, Paredes- Saharopulos O, González-Amaro R: Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol 2005, 141:372-380.
45. Sallusto F, Geginat J, Lanzavecchia A: Central memory and effector memory T cell subsets: Function, generation and maintenance. Annu Rev Immunol 2004, 22:745-763.
46. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, Klareskog L, Ulfgren AK: Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005, 52:61-72.
47. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M: Infliximab induces potent anti-inflammatory responses by outside-to-inside signal through transmembrane TNF-α. Gastroenterology 2005, 128:376-392.
48. Kirchner S, Holler E, Haffner S, Andreesen R, Eissner G: Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 2004, 28:67-74.